Regulated induced proximity targeting chimeras—RIPTACs—A heterobifunctional small molecule strategy for cancer selective therapies
Authors:
Top Cited Papers
- 7 August 2024
- journal article
- research article
- Published by Elsevier in Cell Chemical Biology
- Vol. 31 (8) , 1490-1502.e42
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health (R35 CA197589)
- American Cancer Society
- Howard Hughes Medical Institute
This publication has 26 references indexed in Scilit:
- Bifunctional Small Molecules That Induce Nuclear Localization and Targeted Transcriptional RegulationJournal of the American Chemical Society, 2023
- Why 90% of clinical drug development fails and how to improve it?Acta Pharmaceutica Sinica B, 2022
- Anticancer Drugs Approved by the US Food and Drug Administration From 2009 to 2020 According to Their Mechanism of ActionJAMA Network Open, 2021
- Overview of approved CAR‐T therapies, ongoing clinical trials, and its impact on clinical practiceeJHaem, 2021
- Rationalizing PROTAC-Mediated Ternary Complex Formation Using RosettaJournal of Chemical Information and Modeling, 2021
- Targeting pan-essential genes in cancer: Challenges and opportunitiesCancer Cell, 2021
- Structure driven compound optimization in targeted protein degradationDrug Discovery Today: Technologies, 2020
- SPR-Measured Dissociation Kinetics of PROTAC Ternary Complexes Influence Target Degradation RateACS Chemical Biology, 2019
- Comprehensive Characterization of Cancer Driver Genes and MutationsCell, 2018
- Characterization of the FKBP·Rapamycin·FRB Ternary ComplexJournal of the American Chemical Society, 2005